Tibsovo (ivosidenib) vs Pemazyre (pemigatinib)
Tibsovo (ivosidenib) vs Pemazyre (pemigatinib)
Tibsovo (ivosidenib) is an oral medication specifically approved for the treatment of acute myeloid leukemia (AML) with a susceptible IDH1 mutation in adult patients, as well as for cholangiocarcinoma with an IDH1 mutation. Pemazyre (pemigatinib), on the other hand, is an oral kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. When deciding between the two medications, it is crucial to consider the specific type of cancer and its genetic mutations, as each drug targets different mutations and is used for different indications.
Difference between Tibsovo and Pemazyre
| Metric | Tibsovo (ivosidenib) | Pemazyre (pemigatinib) |
|---|---|---|
| Generic name | Ivosidenib | Pemigatinib |
| Indications | Acute myeloid leukemia (AML) with a susceptible IDH1 mutation | Cholangiocarcinoma with FGFR2 fusions or rearrangements |
| Mechanism of action | Inhibitor of the isocitrate dehydrogenase-1 (IDH1) enzyme | Fibroblast growth factor receptor (FGFR) inhibitor |
| Brand names | Tibsovo | Pemazyre |
| Administrative route | Oral | Oral |
| Side effects | Fatigue, leukocytosis, arthralgia, diarrhea, dyspnea, edema, nausea, mucositis, QT interval prolongation | Hyperphosphatemia, alopecia, diarrhea, fatigue, dysgeusia, nausea, constipation, stomatitis, dry mouth, decreased appetite |
| Contraindications | Known hypersensitivity to ivosidenib or any of its components | Known hypersensitivity to pemigatinib or any of its components |
| Drug class | IDH1 inhibitor | FGFR inhibitor |
| Manufacturer | Agios Pharmaceuticals, Inc. | Incite Corporation |
Efficacy
Efficacy of Tibsovo (Ivosidenib) in Bile Duct Cancer
Tibsovo (ivosidenib) is an oral medication that targets specific genetic mutations known as isocitrate dehydrogenase-1 (IDH1) mutations. In the context of bile duct cancer, or cholangiocarcinoma, Tibsovo has shown efficacy for patients whose tumors harbor an IDH1 mutation. This subset of patients, although relatively small, can benefit significantly from this targeted therapy. The FDA approved Tibsovo for the treatment of adult patients with IDH1-mutated cholangiocarcinoma following the results of clinical trials that demonstrated a favorable response rate and a disease control rate in patients who had progressed on previous therapies.
In clinical studies, Tibsovo has shown to induce partial responses and stable disease in a proportion of patients with IDH1-mutated bile duct cancer. The median duration of response has been reported to be meaningful, providing a therapeutic option for patients with this specific genetic profile. It is important to note that the efficacy of Tibsovo is contingent upon the presence of an IDH1 mutation, and therefore, genetic testing is essential before initiating treatment with this agent.
Efficacy of Pemazyre (Pemigatinib) in Bile Duct Cancer
Pemazyre (pemigatinib) is another targeted therapy that has demonstrated efficacy in the treatment of bile duct cancer, specifically in patients with tumors that exhibit fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements. Pemazyre is an FGFR inhibitor that has been approved by the FDA for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. The approval was based on the overall response rate and duration of response observed in clinical trials.
In the clinical trials that led to its approval, Pemazyre showed a significant overall response rate in patients with FGFR2 fusion-positive cholangiocarcinoma. The treatment has been associated with a clinically meaningful improvement in progression-free survival compared to chemotherapy. Similar to Tibsovo, the use of Pemazyre is highly dependent on the genetic characteristics of the tumor, making the identification of FGFR2 fusions or rearrangements critical before initiation of therapy. Pemazyre offers a new avenue of hope for patients with this specific genetic alteration, who have limited treatment options after first-line therapy.
Regulatory Agency Approvals
Tibsovo
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Pemazyre
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Tibsovo or Pemazyre today
If Tibsovo or Pemazyre are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us